



# Costs and efficiency of integrating HIV/AIDS services with other health services: a systematic review of evidence and experience

Sedona Sweeney,<sup>1</sup> Carol Dayo Obure,<sup>1</sup> Claudia B Maier,<sup>2</sup> Robert Greener,<sup>2</sup> Karl Dehne,<sup>2</sup> Anna Vassall<sup>1</sup>

► An additional appendix is published online only. To view this file please visit the journal online (<http://sti.bmj.com/content/88/2.toc>).

<sup>1</sup>Social and Mathematical Epidemiology Group (SAME), Department of Global Health of Development, London School of Hygiene and Tropical Medicine, London, UK

<sup>2</sup>UNAIDS, Geneva, Switzerland

## Correspondence to

Sedona Sweeney, Global Health and Development, London School of Hygiene and Tropical Medicine, WC1E 7HT, London, UK; [sedona.sweeney@lshtm.ac.uk](mailto:sedona.sweeney@lshtm.ac.uk)

This article is an abbreviated version of: <http://integra.wp.tincan.co.uk/wp-content/uploads/2012/01/UNAIDS-Report.pdf>

Accepted 7 November 2011  
Published Online First  
8 December 2011

## ABSTRACT

**Objectives** To review the literature on the potential efficiency gains of integrating HIV services with other health services.

**Design** Systematic literature review. Search of electronic databases, manual searching and snowball sampling. Studies that presented results on cost, efficiency or cost-effectiveness of integrated HIV services were included, focusing on low- and middle-income countries. Evidence was analysed and synthesised through a narrative approach and the quality of studies assessed.

**Results** Of 666 citations retrieved, 46 were included (35 peer reviewed and 11 from grey literature). A range of integrated HIV services were found to be cost-effective compared with 'do-nothing' alternatives, including HIV services integrated into sexual and reproductive health services, integrated tuberculosis/HIV services and HIV services integrated into primary healthcare. The cost of integrated HIV counselling and testing is likely to be lower than that of stand-alone counselling and testing provision; however, evidence is limited on the comparative costs of other services, particularly HIV care and treatment. There is also little known about the most efficient model of integration, the efficiency gain from integration beyond the service level and any economic benefit to HIV service users.

**Conclusions** In the context of increasing political commitment and previous reviews suggesting a strong public health argument for the integration of HIV services, the authors found the evidence on efficiency broadly supports further efforts to integrate HIV services. However, key evidence gaps remain, and there is an urgent need for further research in this area.

## INTRODUCTION

Integration is a growing priority in the context of the AIDS response. HIV/AIDS is intrinsically linked to many other health problems. Integration has the potential to improve the quality and continuity of care for those living with HIV or bring HIV services to those who would otherwise not have access to them.<sup>1 2</sup> For some interventions, such as prevention of mother-to-child transmission of HIV (PMTCT) or prevention and treatment of tuberculosis (TB) co-infection, integration is clinically essential. The integration of HIV services is supported by a wide range of evidence on its clinical and public health benefit.<sup>3–7</sup> These highlight its benefits to patients with co-morbidities, benefits in

terms of continuity of care and increased access to HIV services. It has therefore been called for in a number of global policies and high-level position papers, most recently in the 2011 UN Declaration on HIV/AIDS.<sup>8</sup> It is also commonly assumed that integration can improve programme efficiency.<sup>2 9 10</sup> This is of particular interest in the current economic climate, as many countries are seeking to rationalise their health-related expenditure. However, to date, the evidence base to support this assertion remains unclear, despite the numerous reviews that focus on HIV integration more generally.<sup>9–18</sup> This paper therefore summarises the current evidence on the impact of integration of HIV services on the efficiency of health services, focusing on low- and middle-income countries.

Integration has been approached differently in a wide variety of settings, making the concept of integration difficult to tie down. Although there has been some consensus recently in the field of sexual and reproductive health (SRH) on terminology,<sup>19</sup> there remain several differing discourses on integration.<sup>12 20–23</sup> The most common understanding relates to horizontal integration or integration at the point of service delivery; this can range from structured referrals to physical incorporation providing a one-stop approach.<sup>21</sup> Integration can also be seen as part of a wider system of co-ordination at the policy and planning, human resources and financing levels, sometimes referred to as linkages.<sup>19</sup> For the purposes of this review, we use the UNAIDS definition of programme integration: 'joining together different kinds of services or operational programmes in order to maximize outcomes, e.g. by organizing referrals from one service to another or offering one-stop comprehensive and integrated services'.<sup>W1</sup> This includes services from a singular provider and from separate providers (within one site) where there is a clearly functional referral system.

Economic theory suggests several potential efficiency advantages at various levels of a health system arising from the integration of HIV and other health services.<sup>15 24</sup> Integration has the potential to improve both technical efficiency (providing services or producing outputs at the lowest cost) and allocative efficiency (achieving health outcomes at a low cost). Technical efficiency focuses on using the right mix of resources to produce health services and can be assessed by measuring the unit cost of HIV services. Allocative efficiency is also concerned with whether the right

mix of health services are provided and is commonly assessed using measures of cost-effectiveness.

Integration has the potential to improve technical efficiency through economies of scope and scale. Economies of scope, or reductions in HIV service costs from combining services, may be found through shared use of a common infrastructure, overheads and certain 'indivisible' operational resources. Economies of scale, or reductions in HIV service costs associated with increased scale of service provision, may be found where integration enables expansion of service coverage to clients who have not previously accessed them.

Beyond this, as stated above, HIV service integration may be clinically essential for the provision of cost-effective services for those with HIV (eg, the integration of HIV counselling and testing (CT) into antenatal care (ANC) services is clinically required for the provision of PMTCT). Integration can thus also contribute to an overall improvement of the allocative efficiency of HIV services. Moreover, integration may enable further efficiency gains beyond the service level. Box 1 further describes the potential effect of integration at each level of a health system, loosely based on the framework to describe integration developed by Atun *et al.*<sup>25</sup>

Economic evidence on integration from other sectors suggests that integration is likely to produce efficiency gains when '(1) goods/services are complementary, (2) there is a low marginal cost of added service, (3) consumers value all services and (4) there is a low correlation in demand for different services'.<sup>15</sup> The integration of HIV and other health services potentially meets most of these requirements. First, HIV and TB/SRH/maternal and child health services are complementary

services as they address co-infections, are provided at similar health services levels and may affect the same persons.<sup>26</sup> Second, there is a potentially low marginal cost of integrated services where clinic space exists and staff already have much of the essential knowledge and skills.<sup>15</sup> Third, HIV services may be valued by clients seeking general services, and people living with HIV may have a wide range of other unmet health needs.<sup>27–30</sup> Fourth, there may be a low correlation in existing demand where groups of clients seeking other health services may not seek HIV-related services independently.<sup>15</sup>

## METHODOLOGY

We conducted a systematic review of published and grey literature to identify studies presenting the costs and cost-effectiveness of integrated HIV services. Searches were conducted on EconLit, Global Health, Eldis and PubMed databases. Database searches were restricted to studies written in English, potentially introducing some bias to our findings. We put no date restriction on our search but found no studies published before 1990 fit our inclusion criteria. We used two different search strings to identify studies in PubMed, as listed in box W1 in the online appendix. In order to minimise the effect of publication bias,<sup>W2</sup> we also conducted manual searches of websites of key organisations involved in HIV-related research or cost-effectiveness studies.<sup>1</sup> We found additional references through a 'snowball sampling' process.

Inclusion criteria were designed to retain all studies, which examined the costs or efficiency consequences of integration. We focused on studies set in low- or middle-income countries as defined by the World Bank.<sup>W3</sup> We found only one article examining integration for services targeted at populations at a higher risk of exposure to HIV; so we expanded our search to include high-income countries for this topic as we felt that it is important to include evidence on integration relevant for concentrated epidemic settings. Study inclusion/exclusion was not blinded. Cases where there was uncertainty or disagreement about the inclusion of a study were discussed between the authors and a consensus reached.

Data extraction was divided between two authors, with uniform tables filled for all included studies. We evaluated the quality of included studies using 'Drummond's checklist' to evaluate the quality of economic articles.<sup>W4</sup> Criteria for quality analysis also included alternatives compared, whether all relevant costs were included, source of cost and effectiveness estimates and the inclusion and type of sensitivity analysis conducted. We expanded Drummond's criteria on cost measurement to include study scale. Studies determined to be of poor quality were not excluded from the review, as we wanted to present the full range of studies, including a comment on overall quality of work in this area. However, study quality was taken into account when reporting the strength of the evidence to date and interpreting our findings. Due to the complexity of integration and differences in measures, we did not attempt to quantitatively synthesise the evidence. Instead we took a narrative approach in data synthesis, as has been recommended for reviews of health systems/organisational interventions where findings are too heterogeneous for meta-analysis.<sup>W5</sup> This paper is adapted from a full review report that can be found on (<http://www.integrainitiative.org/>). In addition, a full list of references and several additional tables and

### Box 1 Potential efficiency gains from integration

1. Integration at the *governance level* (such as co-ordination of strategic and operation planning and performance level) may improve technical efficiency by sharing scarce resources, such as skilled planners and managers. Joint or co-ordinated planning and management, monitoring and evaluation, and reporting may also improve allocative efficiency, as (or if) planners allocate their scarce resources across interventions taking into account the relative cost-effectiveness of services.
2. At the *financing level*, integration may improve technical efficiency by merging the costs of separate financing systems. Co-ordinated financing systems may also reduce perverse incentives that may be created by competing programmes and thus impact allocative efficiency.
3. At the *health management systems level*, integration can facilitate improvements in technical efficiency through reductions in management systems costs. This can include joint procurement, sharing of middle managers, joint training and supervision, sharing of information, education and communication materials, and joint management information systems.
4. At the *facility level*, integration can contribute to reductions in facility costs resulting from joint utilisation of fixed factors of production.
5. For *patients*, integration may lead to less fragmented services, higher levels of continuity of care, better referral systems and possibly reductions in patient/community-level costs resulting from fewer visits to facilities, greater proximity of services and reduced delays in accessing treatment.

<sup>1</sup>Organisations include Abt Associates, Population Services International, Family Health International, Health and Life Sciences Partnership, Management Sciences for Health, PATH, Center for Strategic and International Studies, Population Services International, Research for Development, John Snow International, International Planned Parenthood Foundation, Population Council and Options.

figures can be found on (<http://sti.bmj.com/content/88/2.toc>); these are prefixed with a 'W' in this paper.

## RESULTS

### Study overview

Database searches returned a total of 588 results. Manual searches and snowballing retrieved an additional 78 articles, totalling 666 citations in full. Fifty-one duplicates and 451 clearly irrelevant titles were excluded in the first round of title/abstract review. Reasons for exclusion included high-income setting, had nothing to do with HIV/AIDS, commentary or review paper and intervention was clearly not integrated. One hundred and sixty-four abstracts were evaluated, and full text was read and reviewed for 55 citations in total. A total of 46 studies were retained after review of the full text. A flow chart of this review selection process is contained in the online appendix (figure W1).

Of 46 studies retained, 35 were peer-reviewed and 11 were grey literature. Studies included cost analyses, cost-effectiveness analyses and least-cost analyses. Most studies included all relevant costs in their analysis, though costing methods varied. Studies either evaluated an integrated intervention against a 'do-nothing' comparator in which no treatment or intervention was offered or compared alternative integrated intervention strategies (such as comparative evaluations of isoniazid preventive therapy (IPT) with and without TB screening). Nine studies conducted a direct comparison of integrated and stand-alone services providing the same set of interventions. Studies used a wide variety of service output and outcome measures for cost and cost-effectiveness. For example, cost-effectiveness was measured using the cost per TB case averted, HIV infection averted and disability-adjusted life year averted. Disability-adjusted life years are calculated as the sum of years of life lost and years of life lived in a state of less than full health. Study quality is summarised in table W1.

We divided studies into five major topic headings. First is HIV CT integrated into other health services. This includes both voluntary and provider-initiated CT for HIV, integrated into primary healthcare (PHC), SRH, home-based care, MCH and TB services. Second is TB services integrated into HIV care and treatment, including IPT, intensified case finding and TB treatment. These services often used CT as an access point for TB services, although several studies also included referral from any TB unit to the CT unit, indicating two-way collaboration. Third is HIV care and treatment integrated into general health services and community-based care (including palliative care, cotrimoxazole preventive therapy, PMTCT and antiretroviral therapy (ART)). The fourth examined the integration of family planning (FP) into services for HIV-positive individuals, including PMTCT and HIV care and treatment. Finally, the last topic examined HIV care and treatment and preventive outreach services integrated into other health services for populations at higher risk of HIV exposure, who may have different needs/interactions with the healthcare system from the general public.

### HIV CT integrated into other health services

We identified 17 studies which evaluated the costs and/or cost-effectiveness of the integration of CT into other health services (table 1), 10 of which were peer-reviewed and seven of which were grey literature. Five of the studies<sup>W6–10</sup> compared the cost of integrated services with those of stand-alone services, enabling an assessment of technical efficiency gains. The remaining 12 studies<sup>W11–22</sup> provide cost estimates for different models of integrated CT or contribute to the evidence base on the cost-effectiveness of an integrated service package.

Of the five studies which present a non-integrated comparator, three were conducted in Kenya, one in Uganda and one in India. The three Kenyan studies examined introducing CT into FP/PHC settings. The Ugandan study<sup>W10</sup> compared different CT strategies including stand-alone, hospital-based and facility-based home outreach. Finally, the Indian study<sup>W8</sup> examined the economic consequences of merging existing SRH and HIV services. All five studies found that unit costs were consistently lower for integrated services than stand-alone services, with savings between 31% and 79% of stand-alone costs. However, they were all conducted at a relatively small scale. Generally, the studies that examined CT as part of integrated service packages (ANC/PMTCT and TB/HIV) found these services to be cost-effective compared with a 'do-nothing' alternative. In addition, one study<sup>W22</sup> reported significant potential future cost savings in ART and PMTCT services from integrating CT in ANC compared with a do-nothing alternative.

### TB services integrated into HIV care

We found two models<sup>W23–W24</sup> and seven empirically based studies (some involving limited modelling)<sup>W17–W19–W25–29</sup> examining the costs and/or cost-effectiveness of integrating TB and HIV services (table 2). All nine studies were peer-reviewed. Studies largely evaluated elements of the '3 I's' strategy, an integrated approach to reduce the burden of TB on HIV-positive clients through intensified TB case finding, IPT and infection control for TB, as recommended by WHO (2008).<sup>W30</sup> Intervention elements included IPT (in some cases targeted with a tuberculin skin test), intensified case finding and cotrimoxazole preventive therapy, integrated with CT or HIV care and treatment services. CT was commonly used as an access point for TB services, although in some cases (eg, ProTEST), the collaboration was bi-directional (including referral from TB to HIV and vice versa). None of the studies compared a stand-alone versus integrated option, as integration is clinically required to deliver the full range of TB/HIV services to co-infected patients. Five of the seven empirical studies focused on establishing the incremental cost-effectiveness of integrated TB/HIV services compared with 'do nothing'. All studies were set in the context of generalised epidemics in sub-Saharan Africa, with the exception of one from Cambodia.<sup>W29</sup>

The majority of studies found that integrated TB/HIV care was highly cost-effective. Five studies included the estimated TB treatment cost savings from preventive therapy; three of these found the intervention to be cost saving. None of the studies presented a before and after evaluation of changes in average costs of services as a consequence of integration or examined different models of integration, so no conclusions on technical efficiency can be drawn.

### HIV care and treatment integrated into general health services

We found 18 studies<sup>W16–W17–W21–W31–45</sup> evaluating the costs and/or cost-effectiveness of HIV care and treatment integrated into general health services, community-based care or PHC (table 3). Sixteen studies were peer-reviewed and two were grey literature. Only one study (Rosen *et al*)<sup>W39</sup> considered a non-integrated alternative. Of the remaining studies, 11 specified the model of integrated service delivery in use and six specified provision in conjunction with PHC but gave few details of service delivery organisation.

All of the 11 studies that specify integrated service delivery examine HIV care and treatment in a one-stop-shop setting, except Kitajima *et al*<sup>W38</sup> (which evaluated referral to different providers within the same facility). Generally, the studies were

**Table 1** CT studies

Citation	Author	Date	Country	HIV prevalence (%)	Target population	Integration detail	Study scale	Costing methods	Intervention unit costs	Comparator units costs	Unit
Studies with a non-integrated comparator											
W6	Twarir	1996	Kenya	10.50	MCH/FP clients	Referral Different structures	Pilot 2 clinics	Financial Incremental costs Health services perspective	\$12.77	\$18.42	Client accessing all services
W7	Forsythe	2002	Kenya	7.90	General population	One stop Same structure	Pilot 3 PHC clinics	Economic Incremental costs Health services perspective	\$11—\$21	\$18—\$35*	Person tested
W8	Das	2007	India	0.40	SRH clients	One stop Same structure	Pilot 1 clinic	Financial Full costs Health services perspective	\$3.51	\$5.24	Client accessing RH and CT services
W9	Liambila	2008	Kenya	6.70	FP clients Hospitals and health centres	(1) Referral Same or Different structures (2) One stop Same structure	(1) Pilot 14 sites (2) Pilot 9 sites	Financial Incremental costs Health services perspective	(1) NA (2) (a) \$7.21 (b) \$11.86 (c) \$12.27	34.77*	(1) NA (2) (a) Person tested (hospital) (b) Person tested (health centre) (c) Person tested (dispensary)
W10	Menzies	2009	Uganda	6.50	(1) Hospital clients (2) Families of HIV- positive clients/ facility-based home outreach (3) General population/ facility-based home outreach	(1) One stop Same structure (2) One stop Same structure (3) One stop Same structure	(1) Pilot 1 hospital (2) Pilot 1 outreach site (3) Pilot 1 outreach site	Economic Full costs (assumed) Health services perspective	(1) (a) \$12.43 (b) \$15.68 (c) \$45.87 (2) (a) \$14.74 (b) \$15.47 (c) \$246.53 (3) (a) \$8.82 (b) \$9.80 (c) \$174.46	(a) \$20.50 (b) \$31.61 (c) \$107.05	(a) HCT client (b) New CT client (c) HIV-positive individual identified
CT integrated into PHC/SRH											
W11	Thielman	2006	Tanzania	6	General population Community level	(1) One stop (free) Same structure (2) One stop (fee based) Same structure	Pilot 1 scheme	Incremental Economic costs Health services perspective	(1) (a) \$8.80 (b) \$5.40 (2) (a) \$14.22 (b) \$8.72	(a) Person tested (b) DALY averted	
W12	Chee	2006	Zambia	13.8	Antenatal clients Community and clinic level	One stop Same structure	Pilot	Full Financial costs Health service perspective	(a) \$3.24 (b) \$427	(a) Beneficiary (b) New CT acceptor	
W13	Homan	2006	South Africa	18.10	General population FP clinics	One stop and referral Same structure	Pilot 18 clinics	Incremental Financial costs Health services perspective	(a) \$5679—\$7950 (b) \$1817	(a) Staff training (per clinic) (b) Annual supplies (per clinic)	Person trained annually
W14	Reynolds	2006	Kenya	6.60	CT clients Clinic/Hospital	One stop Same structure	Pilot 14 sites	Incremental Economic costs Health service perspective	\$399		

Continued

**Table 1** Continued

Citation	Author	Date	Country	HIV prevalence (%)	Target population	Integration detail	Study scale	Costing methods	Intervention unit costs	Comparator unit costs	Unit
W15	Mullick	2008	South Africa	29.10	Family planning clients Clinic/hospital	(1) One stop Same structure (2) Referral Different structures	Pilot 18 sites	Incremental Economic costs Health service perspective	(1) \$7724 (2) \$5452		Additional investment required
W16	Bratt	2011	Zambia	13.50	(1) Hospital (2) Hospital (3) Clinic (4) Hospital (5) Health centre (6) Health centre (7) District hospital (8) Clinic (9) Health centre (10) District hospital (11) Mission hospital (12) Central clinic	One stop Same structure	At scale 12 facilities costed 219 facilities existing	Full Economic costs Health service perspective	(1) \$9.23 (2) \$9.89 (3) \$24.54 (4) \$14.18 (5) NA (6) \$19.24 (7) \$21.83 (8) \$26.04 (9) \$30.25 (10) NA (11) \$20.29 (12) \$14.69		Visit
CT integrated into TB											
W17	Hausler	2006	South Africa	17	(1) CT, ANC, TB and STI clients Community health centre (2) CT, ANC, TB and STI clients PHC clinics Patients with active TB National model	One stop and referral Same structure	Pilot 3 sites costed 12 facilities existing	Full Economic costs Health service perspective	(1) (a) \$29 (b) \$113 (c) \$216 (2) (a) \$38 (b) \$136 (c) \$260		(a) Person accessing ProTest (b) HIV infection averted by CT (c) TB case prevented by CT
W18	Uhler	2010	India	0.3	Patients with active TB National model	(1) Selective referral Different structures (2) Targeted referral Different structures (3) Universal routine referral	Model	Full Costing not clear Cost perspective not clear	(1) \$103 (2) \$114 (3) \$124		Person lifetime
W19	Vassall	2010	Ethiopia	4.40	TB/HIV patients Hospitals	Different structures One stop and referral Same structure	Pilot 3 hospitals costed 9 facilities existing	Full Economic costs Patent perspective	(1) \$147 (2) \$326 (3) \$193		(a) Patient (TB only) (b) Patient (HIV only) (c) Patient (TB/HIV)

Continued

**Table 1** Continued

Citation	Author	Date	Country	HIV prevalence (%)	Target population	Integration detail	Study scale	Costing methods	Intervention unit costs	Comparator units costs	Unit
CT as an entry point for PMTCT											
W20	Kumar	2006	India	0.40	(1) ANC clients (universal) (2) ANC clients (targeted)	One stop Same structure	Model	Incremental Economic costs Health service and societal costs	(1) (a) \$663.93 (b) \$49.82 (2) (a) \$543.02 (b) \$23.35		(a) HIV infection prevented (b) Year reduction on PYLLs
W21	Sweet	2004	(1) Botswana (2) Cote d'Ivoire (3) Kenya (4) Rwanda (5) Tanzania (6) Uganda (7) Zambia (8) Zimbabwe	(1) 25.8 (2) 5.3 (3) 7.1 (4) 3.2 (5) 6.4 (6) 6.4 (7) 14 (8) 19.8	ANC clients	One stop Same structure	Pilot	Incremental Costing not clear Health services perspective	(1) (a) \$2329 (b) \$75 (2) (a) \$11 924 (b) 399\$ (3) (a) \$5528 (b) \$180 (4) (a) \$2406 (b) \$85 (5) (a) \$2942 (b) \$99 (6) (a) \$6255 (b) \$216 (7) (a) \$3305 (b) \$111 (8) (a) \$4602 (b) \$148		(a) Perinatal HIV infection averted (b) DALY averted
W22	Perchal	2006	(1) Ethiopia (2) Ukraine	(1) 14–16 (2) 1.1	ANC clients	One stop Same structure	Pilot	Incremental Economic costs Health services perspective	(1) (a) \$25.74 (b) \$6.92 (2) (a) \$8.72 (b) \$6.25		(a) User in the first year (b) User in subsequent years

\*Previously published cost estimate.

Costs adjusted to 2010 USD.

ANC, antenatal care; CT, counselling and testing; DALY, disability-adjusted life year; FP, family planning; MCH, maternal and child health; PHC, primary healthcare; PMTCT, prevention of mother-to-child transmission; SRH, sexual and reproductive health; STI, sexually transmitted infection; TB, tuberculosis; RH, reproductive health; PYLL, potential years of life lost.

**Table 2** TB studies

Citation	Author	Date	Country	HIV prevalence (%)	Target population	Integration detail	Scale	Costing methods	Unit costs and cost-effectiveness	Unit
<b>Models</b>										
W23	Masobe	1995	South Africa	6.10	HIV-positive individuals	Integration not clear	Model Scale not clear	Costing not clear Full costs (assumed) Health services perspective	(1) \$42 980 118 (2) \$24 006 909	(1) Do nothing cost over 8 years (2) Intervention cost over 8 years QALY saved over do-nothing
W24	Bell	1999	Uganda	7.30	HIV-positive individuals w/ pos TST	Integration not clear (1) IPT (INH for 6 months) (2) IPT (INH + RIF for 3 months) (3) RIF + PZA for 2 months	Model Scale not clear	Costing not clear Incremental costs Health services perspective	(1) \$156 (2) \$376 (3) \$356	
<b>Empirical studies</b>										
W25	Foster	1997	Zambia	14.50	Individuals presenting for CT	(1) Referral from CT centre (2) Referral from CT centre (3) Referral from STD clinic (4) Occupational therapy (5) Occupational therapy (6) Referral from CT centre One stop Same structure	Model Scale not clear	Costing not clear Incremental costs Health services and patient wages	(1) -\$25 to \$34 (2) -\$53 to -\$39 (3) -\$19 to \$54 (4) -\$30 to \$23 (5) -\$55 to -\$44 (6) \$2-\$100	TB case prevented
W26	Shrestha	2006	Uganda	6.30	Newly diagnosed HIV-positive patients (1) IPT with TST, 6-month regimen (2) IPT with TST, 9-month regimen (3) IPT without TST, 6-month regimen (4) IPT without TST, 9-month regimen CT, ANC, TB and STI clients (1) Community health centre (2) PHC clinic	One stop Same structure	Pilot 1 clinic	Financial Incremental costs Health services perspective	(1) \$23.62 (2) \$61.19 (3) \$19.68 (4) \$46.16	HIV-positive patient
W17	Hausler	2006	South Africa	17	STI clients (1) Community health centre (2) PHC clinic	One stop Same structure	Pilot 3 facilities costed 12 facilities existing	Economic Full costs Health services perspective	(1) (a) \$29 (b) \$805 (c) \$1166 (2) (a) \$38 (b) \$391 (c) \$586	(a) Person accessing Pro TEST (b) TB case prevented by ICF (c) TB case prevented by IPT
W27	Shrestha	2007	Uganda	6.30	Newly diagnosed HIV-positive patients (1) IPT with TST (2) IPT without TST	One stop Same structure	Pilot 2 clinics	Financial Incremental costs Health services perspective	(1) (a) \$121.18 (b) \$102 (2) (a) \$159.34 (b) \$105	(a) Client (b) QALY gained over control

Continued

Table 2 Continued

Citation	Author	Date	Country	HIV prevalence (%)	Target population	Integration detail	Scale	Costing methods	Unit costs and cost-effectiveness	Unit
W28	Terris-Prestholt	2008	Zambia	13.60	Newly diagnosed HIV-positive patients	One stop Same structure	Pilot 1 clinic, 1 hospital	Economic Full costs Health services perspective (assumed)	(1) (a) \$14 (b) \$31 (c) \$56 (2) (a) \$35 (b) \$40 (c) \$56	(a) Person pre-test counselled for CT (b) Person completing IPT (c) Annually per client
W29	Sutton	2009	Cambodia	0.50	HIV-positive individuals	One stop Same structure	Pilot 4 hospitals	Economic Full costs Health services perspective	(a) \$99.72 (b) \$27.64 (c) \$398.84 (d) \$1049.47	(a) TB case detected by ICF (b) Person completing IPT (c) TB case prevented by ICF (d) TB case prevented by IPT
W19	Vassall	2010	Ethiopia	4.40	TB/HIV patients	One stop Same structure	Pilot 3 hospitals costed 9 sites existing	Economic Full costs Patient perspective	(a) \$147/patient (b) \$326/patient (c) \$193	(a) Patient (TB only) (b) Patient (HIV only) (c) Patient (TB/HIV)

All costs adjusted to 2010 USD.

ANC, antenatal care; CT, counselling and testing; ICF, intensified case finding; IPT, isoniazid preventive therapy; STD, sexually transmitted infection; TB, tuberculosis; TST, tuberculin skin test; w/pos TST, with positive tuberculin skin test; INH, isoniazid; PZA, pyrazinamide; RIF, rifampin.

set in the context of generalised epidemics in sub-Saharan Africa, although two studies consider concentrated epidemics: one in Mexico<sup>W42</sup> and one in Thailand.<sup>W38</sup> The majority of studies conclude that integrated HIV treatment and care services are feasible and cost-effective.

The one comparative study by Rosen *et al*<sup>W39</sup> found that stand-alone sites were more expensive per patient treated than some integrated models (hospital and general practitioner based) but less expensive than an integrated PHC model. When costs per patient in care and 'responding to treatment' were compared, the results for the stand-alone and integrated PHC models were equivocal and the general practitioner model was found to be more expensive. However, as this study includes only four sites (each with differing methods, financing sources and settings), no firm conclusions on whether integration or stand-alone provision of HIV care and treatment is more efficient can be drawn.

### FP for HIV-positive individuals

Four studies estimated the potential cost savings from provision of FP to HIV-positive individuals through integrating FP services within PMTCT<sup>W46–48</sup> or HIV care and treatment<sup>W49</sup> programmes, two of which were peer-reviewed (table 4). All studies modelled costs at the national level in the context of generalised epidemics; we found no studies that empirically evaluated models of integrating FP with ART services or comprehensive care centres, despite the widespread existence of such programmes.

All studies found the provision of FP to HIV-positive individuals to be highly cost-effective or cost saving. Most studies estimate substantial savings through prevention of the costs incurred from PMTCT interventions, treatment of perinatal HIV infections, care and support for orphans and vulnerable children, and maternal deaths. No studies compared the unit costs of integrated versus stand-alone FP or HIV care and treatment services or examined the comparative costs of different models of integration.

### HIV services integrated with other health services for populations at a higher risk of HIV exposure

We found three studies evaluating the integration of HIV services into other health services for key populations at higher risk of HIV exposure<sup>W50–52</sup> (table 5). All three studies were peer-reviewed. Studies examined the impact of integration on services targeted towards female sex workers, people who inject drugs, and those with mental health disorders. Two studies, set in the USA,<sup>W50 W51</sup> evaluated integration of mental health and/or substance abuse services into HIV care and treatment, while one set in Tanzania<sup>W52</sup> evaluated four different approaches to provision of HIV/sexually transmitted disease prevention services for sex workers at truck stops. All three studies were conducted on a small scale. Two studies<sup>W51 W52</sup> report lower unit costs per patient for integrated services, although in one, the difference was insignificant. The third study found that costs for integrated care were higher at the majority of sites and often not reimbursable by a third-party payer.

### DISCUSSION

Our results show that a wide range of integrated services are cost-effective and that integration may reduce the costs of delivering some key HIV services. The best quality economic evidence focuses on the cost-effectiveness of HIV services, which require integration from a clinical perspective. This includes offering HIV CT in ANC services as part of the provision of PMTCT, providing TB services to HIV-positive clients and HIV

**Table 3** HIV care and treatment studies

Citation	Author	Date	Country	HIV prevalence	Target population/setting	Integration detail	Intervention scale	Costing methods	Unit costs and cost-effectiveness	Unit
HIV palliative care										
W31	Hansen	1998	Zimbabwe	26.30	Facility-based home outreach	One stop Same structure	At scale 4 schemes costed 67 schemes existing	Economic Full costs Health services perspective	(1) \$191 (2) \$465.9 (3) \$509.7 (4) \$271.3 \$825.7–\$1249	(1) Home visit (urban) (2) Home visit (rural) (3) Home visit (rural) (4) Home visit (urban) 3 months
W32	Chandler	2004	Rwanda	3.20	Facility-based home outreach (1) Facility-based home outreach (2) Facility-based home outreach (3) Facility-based home outreach (4) Community-based home outreach (5) Community-based home outreach (6) Community-based home outreach (7) Community-based home outreach (8) Community-based home outreach	One stop Same structure	At scale (assumed) 8 schemes costed	Economic Full costs Health service perspective	(1) \$39.08 (2) \$37.21 (3) \$43.01 (4) \$29.26 (5) \$16.15 (6) \$28.49 (7) \$16.21 (8) \$15.21	Client per month
W33	Bikila	2009	Ethiopia	Unknown	HIV patients HIV clinic within district hospital	One stop Same structure	At scale 1 facility costed 272 sites existing	Economic (assumed) Full costs District hospital perspective	(a) \$35 (b) \$92	(a) Patient annually (outpatient) (b) Patient annually (inpatient)
W34	Uys	2002	South Africa	17.70	Community-based home outreach, clinic and hospital care	Not clear	Pilot 7 sites	Economic Incremental costs Health services perspective	\$1209	Patient annually
Cotrimoxazole preventive therapy										
W17	Hausler	2006	South Africa	17	CT, ANC TB and STI clients (1) Community health centre (2) PHC clinic	One stop Same structure	Pilot 3 facilities costed 12 facilities existing	Economic Full costs Health services perspective	(1) (a) \$10 (b) \$53 (2) (a) \$7 (b) \$24	(1) (a) Person per 6 months of treatment (b) Person completing treatment
W35	Pitter	2007	Uganda	6.30	(1) All HIV-positive individuals (2) WHO stages $\geq 2$ (3) CD4 < 500 (4) WHO stages $\geq 2$ or CD4 < 500 facility-based home outreach/hospital	One stop Same structure	Pilot 1 scheme	Economic Incremental costs Health services perspective	(1) \$54.45 (2) \$59.05 (3) \$77.03 (4) \$59.15 Do nothing: \$57.37	Patient annually
										Continued

Table 3 Continued

Citation	Author	Date	Country	HIV prevalence	Target population/setting	Integration detail	Intervention scale	Costing methods	Unit costs and cost-effectiveness	Unit
W36	Yazdanpanah	2005	Cote D'Ivoire	4.80	University hospital and community clinics (1) WHO stage $\geq 3$ (2) WHO stage $\geq 2$ (3) CD4 $\leq 50$ (4) CD4 $\leq 200$ (5) CD4 $\leq 500$ (6) All HIV positive	Not clear	Model Scale not clear	Costing not clear Incremental costs Health service perspective	(1) \$1661 (2) \$1700 (3) \$1752 (4) \$1752 (5) \$1790 (6) \$1700	Person lifetime
PMTCT	Stringer	2000	Sub-Saharan Africa	15% assumed	University hospital and community clinics (1) WHO stages $\geq 3$ (2) WHO stages $\geq 2$ (3) CD4 $\leq 50$ (4) CD4 $\leq 200$ (5) CD4 $\leq 500$ (6) All HIV positive	Not clear	Model Scale not clear	Costing not clear Incremental costs Health service perspective	(1) \$142 (2) \$258 (3) Dominated (4) Dominated (5) Dominated (6) \$193	Life year saved over do-nothing
					(1) (a) ANC clients (targeted therapy) (b) ANC clients (mass therapy) (2) (a) Labour/delivery clients (infant only) (b) Labour/delivery clients (mass therapy)	One stop Same structure	Model Scale not clear	Costing not clear Full costs (assumed) Third-party payer perspective	(1) (a) \$153 886 (b) \$175 493 (2) (a) \$114 415 (b) \$155 850 Do nothing: \$139 240	10000 women
W21	Sweat	2004	(1) Botswana (2) Cote d'Ivoire (3) Kenya (4) Rwanda (5) Tanzania (6) Uganda (7) Zambia (8) Zimbabwe	(1) 25.8 (2) 5.3 (3) 7.1 (4) 3.2 (5) 6.4 (6) 6.4 (7) 14 (8) 19.8	ANC clients	One stop Same structure	Model National	Costing not clear Incremental costs Health services Perspective	(1) \$2329 (2) \$11 924 (3) \$5528 (4) \$2406 (5) \$2942 (6) \$6255 (7) \$3305 (8) \$4602	Perinatal HIV infection averted
			(1) Botswana (2) Cote d'Ivoire (3) Kenya (4) Rwanda (5) Tanzania (6) Uganda (7) Zambia (8) Zimbabwe	(1) 25.8 (2) 5.3 (3) 7.1 (4) 3.2 (5) 6.4 (6) 6.4 (7) 14 (8) 19.8	ANC clients	One stop Same structure	Model National	Costing not clear Incremental costs Health services Perspective	(1) \$75 (2) \$399 (3) \$180 (4) \$85 (5) \$99 (6) \$216 (7) \$111 (8) \$148	DALY averted

Continued

Table 3 Continued

Citation	Author	Date	Country	HIV prevalence	Target population/setting	Integration detail	Intervention scale	Costing methods	Unit costs and cost-effectiveness	Unit
W16	Bratt	2011	Zambia	13.50	(1) Arthur Davison Children's Hospital (2) Ndola Central Hospital (3) Chipokota Mayamba Clinic (4) Kabwe General Hospital (5) Mahatma Gandhi Health Center (6) Kasanda Health Center (7) Kabompo District Hospital (8) St. Kalembe Clinic (9) Mufumbwa Health Center (10) Kawambwa District Hospital (11) Mbereshi Mission Hospital (12) Kawambwa Central Clinic	One stop Same structure	At scale 12 facilities costed 219 facilities existing	Economic Full costs Health services Perspective	(1) NA (2) \$28–\$50 (3) \$20–\$51 (4) NA (5) NA (6) \$20 (7) \$38–\$62 (8) \$73 (9) \$58 (10) NA (11) \$31–\$62 (12) NA	PMCT visit
ART W38	Kitajima	2003	Thailand	1.50	HIV clinics within regional hospitals	Referral Same structure	Pilot 2 hospitals	Financial (assumed) Full costs Third-party payer perspective	(a) \$354 (b) \$420.6	(a) Outpatient visit (b) Inpatient visit
W39	Rosen	2008	South Africa	17.90	(1) ART patients (hospital) (2) ART patients (private ART programme) (3) ART patients (stand-alone HIV clinic) (4) ART patients (PHC clinic)	One stop Same structure	At scale 4 facilities costed	Economic Full costs Health services Perspective	(1) \$831 (2) \$984 (3) \$1024 (4) \$1237	Patient annually
W33	Bikila	2009	Ethiopia	Unknown	HIV patients HIV clinic within district hospital	One stop Same structure	At scale 1 facility costed 272 sites existing	Economic (assumed) Full costs District hospital perspective	(a) \$267 (b) \$33	(a) Patient annually (outpatient) (b) Patient annually (inpatient)
W40	Marseille	2009	Uganda	6.50	HIV patients Facility-based home outreach	One stop Same structure	Pilot 1 HBC scheme	Economic (assumed) Incremental costs Health service perspective	\$696	Incremental DALY averted over CPT only
W41	Renaud	2009	Burundi	3.30	ART patients PHC clinic for HIV positive	One stop Same structure	Pilot 1 facility	Financial (assumed) Incremental costs Health services perspective	(a) \$1389 (b) \$1177 (c) \$1020 (d) \$842 (e) \$805 (f) \$783	(a) Patient in 2003 (b) Patient in 2004 (c) Patient in 2005 (d) Patient in 2006 (e) Patient in 2007 (f) Patient in 2008

Continued

Table 3 Continued

All costs adjusted to 2010 USD.  
ANC, antenatal care; ART, antiretroviral therapy; CT, counselling and testing; DALY, disability-adjusted life year; HBC, home-based care; PHC, primary healthcare; PMTCT, prevention of mother-to-child transmission; STI, sexually transmitted infection; TB, tuberculosis; CPT, cotrimoxazole preventive therapy.

**Table 4** FP studies

Citation	Author	Date	Country	HIV prevalence	Integration detail	Costing methods	Cost savings and cost-effectiveness	Unit
W46	Halperin	2009	(1) 14 high-prevalence countries (subset) (2) 139 countries	Varies	National model Service details not clear	Costing methods not clear Health services perspective	(1) (a) \$562 (b) \$371 (c) \$63 (2) (a) \$714 (b) \$384 (c) \$65	(a) Infant infection averted by perinatal prevention (b) Infant infection averted by pregnancy averted (c) Unintended pregnancy prevented to HIV positive Saved over current practice in the first year
W47	Reynolds	2008	(1) Botswana (2) Mozambique (3) Namibia (4) South Africa (5) Zambia (6) Ethiopia (7) Kenya (8) Rwanda (9) Tanzania (10) Uganda (11) Cote d'Ivoire (12) Nigeria (13) Guyana (14) Haiti (15) Vietnam	(1) 24.1 (2) 16.1 (3) 19.6 (4) 18.8 (5) 17.0 (6) 1.4 (7) 6.1 (8) 3.1 (9) 6.5 (10) 6.7 (11) 4.7 (12) 3.9 (13) 2.4 (14) 2.2 (15) 0.5	National model Service details not clear	Costing methods not clear Health services perspective	(1) \$425 695 (2) \$1 294 921 (3) \$307 759 (4) \$9 036 245 (5) \$2 527 589 (6) \$1 984 179 (7) \$2 890 267 (8) \$427 605 (9) \$1 659 623 (10) \$2 701 425 (11) \$592 230 (12) \$2 119 550 (13) NA (14) \$221 298 (15) \$76 562	
W48	Stover	2003	14 PEPFAR countries	Varies	National model One stop Same structure	Financial (assumed) Incremental costs Health services perspective (assumed)	(a) \$1383 (b) \$2767 (c) \$702 (d) \$383 (e) \$138 (f) \$2767	(a) Child HIV infection averted by PMTCT only (b) Child death averted by PMTCT only (c) Unintended HIV-positive birth averted by PMTCT+FP (d) Child death averted by PMTCT+FP (e) Unintended orphaned child averted by PMTCT+FP (f) Mother's life saved by PMTCT+FP Annual net savings
W49	Stover	2006	(1) Botswana (2) Cote d'Ivoire (3) Ethiopia (4) Guyana (5) Haiti (6) Kenya (7) Mozambique (8) Namibia (9) Nigeria (10) Rwanda (11) South Africa (12) Tanzania (13) Uganda (14) Zambia	(1) 25.3 (2) 4.4 (3) Unknown (4) 1.1 (5) 2.1 (6) 6.6 (7) 11.3 (8) 15 (9) 3.6 (10) 3 (11) 18.1 (12) 6 (13) 6.3 (14) 13.8	National model Service details not clear	Costing methods not clear Health services perspective (assumed)	(1) \$7 300 000 (2) \$3 400 000 (3) \$3 600 000 (4) \$48 000 (5) \$4 900 000 (6) \$4 400 000 (7) \$2 400 000 (8) \$1 100 000 (9) \$3 700 000 (10) \$1 500 000 (11) \$14 000 000 (12) \$1 000 000 (13) \$18 000 000 (14) \$2 900 000	

All costs adjusted to 2010 USD.

FP, family planning; PMTCT, prevention of mother-to-child transmission.

services to those with TB, and making FP services available to HIV-positive clients. There are number of studies that demonstrate the cost-effectiveness and cost savings of these service packages, strongly supporting further scale-up from an economic perspective. However, the cost-effectiveness of these integrated services has generally been demonstrated through models or at the pilot level, and in some areas, there is little empirical evidence to demonstrate efficiency at scale in different contexts. Additionally, none of the studies compare the relative efficiency of different models of delivery, such as one-stop versus structured referrals. None of the studies found examine whether the provision of these services may also result reductions in the unit costs of services through economies of scale or scope, and only a few examine reductions in costs to the patient. The exclusion of these factors is likely to result in an underestimation of the cost-effectiveness of these integrated services.

The integration of both CT and HIV care and treatment into general health services is feasible, and in the case of CT, the evidence consistently demonstrates that integrated CT services are likely to improve technical efficiency. It should be noted,

however, that economic concerns may need to be weighed against issues such as stigma and confidentiality. Where reported, lower CT costs were primarily driven by the improved use of human resources. This suggests that the expansion of CT through existing services may place less of a burden on scarce human resources for health than expansion through stand-alone facilities (although any expansion may still require additional resourcing of staff).

Although there were several studies demonstrating the costs and feasibility of integrated HIV care and treatment, there were no high-quality studies comparing the costs of integrated services with those of stand-alone alternatives. The one study that compared costs across integrated and non-integrated sites was of an insufficient sample size. Due to the variety in services examined and methods used to measure costs, it was also hard to examine whether the costs of integrated HIV care and treatment are higher or lower than those found in other studies costing stand-alone services. Therefore, at present, no firm conclusions can be drawn on the economic benefits of integrating HIV care and treatment.

**Table 5** Other health services studies

Citation	Author	Date	Country	HIV prevalence (%)	Intervention	Scale	Integration detail	Costing methods	Findings summary
W50	Schackman	2011	USA	0.6	Substance abuse treatment	Pilot 10 clinics	One stop Same structure or same clinician	Economic Incremental costs Societal perspective	Median range difference between costs for integrated care and non-integrated care was \$14 (\$67–\$76). Costs for integrated care are higher at 7 sites. At the remaining 2 sites with comparison groups, costs were lower for integrated care due to fewer encounters with physicians.
W51	Weaver	2009	USA	0.6	Treatment for mental health and substance abuse disorders in triply diagnosed patients	RCT 4 hospitals	One stop Same structure	Economic Full costs Health service perspective	Total average monthly cost of health services for the intervention group decreased from \$3235 to \$3052 and for the control group decreased from \$3556 to \$3271, but the decreases were not significant. There is not enough evidence to either limit continued exploration of integration of care for triply diagnosed patients or adopt policies to encourage it.
W52	Nyamuryekung'e	1997	Tanzania	7.9	STD component integrated into HIV prevention programmes at truck stops	Pilot	(1) One stop; in PHC building at special times (2) One stop; integrated into PHC (3) One stop; mobile outreach	Costing not clear Incremental costs Health service perspective	(1) Special times: \$18.35 per client (2) Integrated into PHC: \$17 per client (3) Mobile outreach: \$17.58 per client

All costs adjusted to 2010 USD.  
PHC, primary healthcare; STD, sexually transmitted disease; RCT, randomized controlled trial.

Broadly, we found that the evidence base is weak on assessing any technical efficiency gains from integration, assessing any efficiency impact beyond the service delivery level and assessing any gains from the patient perspective (box 1). Furthermore, the evidence found provides little insight into the most efficient model to employ in different contexts. None of the studies found used traditional econometric methods to estimate economies of scale or scope; where other methods were used, such as before and after comparisons, study quality tended to be poor. This is likely to reflect the fact that these methods require large sample sizes, and there is a scarcity of HIV service cost data from low- and middle-income countries. The application of data envelopment analysis, a non-parametric technique for evaluating efficiency, is beginning to be used in other sectors and could provide a solution where sample sizes are small. Even where broad analytical techniques are available, integration is complex and challenging to represent in quantitative terms. It can be best described as a continuum, progressing from linkages and service co-ordination to full integration of resources and services.<sup>21 25</sup> New techniques, such as developing indices for integration, may provide a way forward. A recent study<sup>21</sup> developed a scale of integration to enable cross-country comparisons of performance. Likewise, work is in progress on the Integra Initiative<sup>ii</sup> to develop an index of integration. However, to date, no studies have yet explored how these scales and indices relate to cost.

This review paper has several limitations. This review only includes accessible published and grey literature and is not necessarily an accurate representation of the full range of cost data available from HIV programmes. Moreover, we were not able to account for the potential impact of political or economic context on study findings. Finally, there was a lack of consistency in cost and efficiency measures (and description of methods) across different studies, again limiting the extent that we were able to interpret and validate study results.

Our results broadly support current recommendations in international policy for integration in HIV services. Studies evaluating WHO collaborative TB/HIV treatment guidelines and 'Three I's' strategy<sup>W30</sup> to reduce the impact of TB on those living with HIV found these interventions to be cost-effective and potentially cost saving. Studies evaluating integration of CT largely support the current WHO policy to expand provider-initiated CT for HIV in PHC settings.<sup>W53</sup> Finally, although there is little empirical evidence available, strong modelling evidence indicates that the steps already taken by a number of countries to integrate FP into services for HIV-positive individuals are likely to be economically beneficial.

Given the significant policy interest in scaling up integration, research on how to implement and expand integrated services is now required. In particular, there is an urgent need to assess the potential for efficiency gains from integrating HIV treatment and care into general health services, requiring large-scale costing studies. There is also almost nothing known about the impact of integration on service provision and efficiency for populations at higher risk of exposure to HIV, a key concern in concentrated epidemic settings. Moreover, for areas where cost-effectiveness is established, we recommend further operational and country-level research to support programme and facility managers. This should focus on identifying which models of integration are most appropriate in different settings, balancing efficiency with other service delivery objectives. Researchers should be

<sup>ii</sup>A project researching HIV/SRH integration funded by the Bill and Melinda Gates Foundation, implemented by the International Planned Parenthood Foundation, London School of Hygiene and Tropical Medicine and Population Council.

## Key messages

- ▶ The evidence to date largely supports current global policy and further efforts to integrate.
- ▶ A number of integrated HIV services have been shown to be cost-effective, though little is known about the comparative efficiency of differing integration models.
- ▶ Evidence gaps remain on economic impact of integration for HIV care and treatment and services for populations at higher risk of HIV exposure.
- ▶ Further research is necessary to identify efficiency gains from integration beyond the service level and economic gains to HIV service users.

challenged not just to assess the extent of gains to be made but also investigate the implications of different models in different settings. Research is also required on the most effective ways for programme managers to implement and promote integration at the facility level. Unfortunately, there is currently insufficient evidence to draw any lessons on the most efficient process of integration, although there are some promising examples of research in this area.<sup>W28</sup> Finally, none of the studies reviewed included efficiency gains at the systems and few at the patient level. The potential in this area may be significant (box 1); it is therefore highly recommended that future studies include these aspects in their assessment of integration.

In summary, given the existing evidence that largely supports HIV integration from a public health and clinical perspective, the findings of this review support further efforts to integrate. However, significant evidence gaps remain. Unfortunately, few of the studies found adequately address the central questions currently concerning many programme managers at this moment in time: not whether to integrate, but when to, how to and which model is most efficient in which setting? Investment in country-based operational research and larger costing studies across a variety of settings is therefore urgently required to support future development of policy and programming in this area.

**Funding** UNAIDS.

**Disclaimer** This research was funded by UNAIDS. The views expressed herein are those of the authors and do not necessarily reflect the official policy or position of UNAIDS.

**Competing interests** None.


**Contributors** All authors were involved in aspects of study design and the analysis and interpretation of data used in the manuscript. SS and AV wrote the first draft of the manuscript. All authors contributed to subsequent drafts of the manuscript and reviewed the final version prior to submission.

**Provenance and peer review** Commissioned; externally peer reviewed.

## REFERENCES

1. **Sylla L**, Bruce RD, Kamarulzaman A, *et al*. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. *Int J Drug Policy* 2007;**18**:306–12.
2. **World Bank**. *HIV/AIDS and Sexual and Reproductive Health Linkages*. 2009. <http://siteresources.worldbank.org/INTPHAAG/Resources/AAGHIVAIDSSRHLinkages409.pdf>
3. **UNAIDS, UNFPA, FHI**. *New York Call to Commitment: Linking HIV/AIDS and Sexual and Reproductive Health*. 2004. [http://www.unfpa.org/upload/lib\\_pub\\_file/321\\_filename\\_New%20York%20Call%20to%20Commitment.pdf](http://www.unfpa.org/upload/lib_pub_file/321_filename_New%20York%20Call%20to%20Commitment.pdf)
4. **WHO, UNFPA**. *The Glion Call to Action*. 2004. [http://www.unfpa.org/upload/lib\\_pub\\_file/333\\_filename\\_glion\\_cal\\_to\\_action.pdf](http://www.unfpa.org/upload/lib_pub_file/333_filename_glion_cal_to_action.pdf)
5. **UNAIDS**. *Intensifying HIV Prevention: A UNAIDS Policy Position Paper*. 2005. [http://data.unaids.org/publications/irc-pub06/jc1165-intensif\\_hiv-newstyle\\_en.pdf](http://data.unaids.org/publications/irc-pub06/jc1165-intensif_hiv-newstyle_en.pdf)
6. **The African Union Commission**. *The Maputo Plan of Action. Special Session of the African Union Conference of Ministers of Health*. 2006. [http://www.unfpa.org/africa/newdocs/maputo\\_eng.pdf](http://www.unfpa.org/africa/newdocs/maputo_eng.pdf)
7. **UNAIDS**. *Joint Action for Results UNAIDS Outcome Framework*. 2011. [http://data.unaids.org/pub/BaseDocument/2010/jc1713\\_joint\\_action\\_en.pdf](http://data.unaids.org/pub/BaseDocument/2010/jc1713_joint_action_en.pdf)
8. **United Nations General Assembly**. Resolution 65/277 [Political Declaration on HIV/AIDS: Intensifying our Efforts to Eliminate HIV/AIDS]. In: *Sixty-fifth Session*. 2011. [http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/06/20110610\\_UN\\_A-RES-65-277\\_en.pdf](http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/06/20110610_UN_A-RES-65-277_en.pdf)
9. **Church K**, Mayhew SH. Integration of STI and HIV prevention, care, and treatment into family planning services: a review of the literature. *Stud Fam Plann* 2009;**40**:171–86.
10. **World Health Organization**, UNAIDS, United Nations Population Fund, *et al*. *Sexual & Reproductive Health and HIV Linkages: Evidence Review and Recommendations*. Geneva: International Planned Parenthood Federation, United Nations Population Fund, UNAIDS, University of California San Francisco, 2009.
11. **Soto TA**, Bell J, Pillen MB; HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study Group. Literature on integrated HIV care: a review. *AIDS Care* 2004;**16** (Suppl 1):S43–55.
12. **Briggs CJ**, Garner P. Strategies for integrating primary health services in middle- and low-income countries at the point of delivery. *Cochrane Database Syst Rev* 2006;(2):CD003318.
13. **French RS**, Coope CM, Graham A, *et al*. One stop shop versus collaborative integration: what is the best way of delivering sexual health services? *Sex Transm Infect* 2006;**82**:202–6.
14. **PATH**. *Convergence of HIV and SRH Services in India: Impacts on and Implications for Key Populations A Literature Review*. New Delhi, India, 2007. <http://www.path.org/publications/detail.php?i=1503>
15. **Ickovics JR**. "Bundling" HIV prevention: integrating services to promote synergistic gain. *Prev Med* 2008;**46**:222–5.
16. **Atun R**, de Jongh T, Secci F, *et al*. A systematic review of the evidence on integration of targeted health interventions into health systems. *Health Policy Plan* 2010;**25**:1–14.
17. **Kennedy CE**, Spaulding AB, Brickley DB, *et al*. Linking sexual and reproductive health and HIV interventions: a systematic review. *J Int AIDS Soc* 2010;**13**:26.
18. **Tudor Car L**, Van-Velthoven MH, Brusamento S, *et al*. Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries. *Cochrane Database Syst Rev* 2011;**6**:CD008741.
19. **IAWG for SRH & HIV Linkages**. *SRH & HIV Linkages Resource Pack*. 2010. [http://www.srhivlinkages.org/en/srh\\_and\\_hiv\\_linkages.html](http://www.srhivlinkages.org/en/srh_and_hiv_linkages.html)
20. **Unger JP**, DePaepe P, Greens A. A code of best practice for disease control programmes to avoid damaging health care services in developing countries. *Int J Health Plann Manage* 2003;**18**(Suppl 1):S27–39.
21. **Shigayeva A**, Atun R, McKee M, *et al*. Health systems, communicable diseases and integration. *Health Policy Plan* 2010;**25**(Suppl 1):4–20.
22. **Atun R**, Bennett DS, Duran A. *When Do Vertical (Stand-Alone) Programmes Have A Place in Health Systems?* Copenhagen, Denmark: World Health Organization Regional Office for Europe, on behalf of the European Observatory on Health Systems and Policies, 2008.
23. **Leichsenring K**. Developing integrated health and social care services for older persons in Europe. *Int J Integr Care* 2004;**4**:e10.
24. **McPake B**, Kumaranayake L, Normand CEM. *Health Economics: An International Perspective*. London: Routledge, 2002.
25. **Atun R**, de Jongh T, Secci F, *et al*. Integration of targeted health interventions into health systems: a conceptual framework for analysis. *Health Policy Plan* 2010;**25**:104–11.
26. **Lush L**, Walt G, Cleland J, *et al*. The role of MCH and family planning services in HIV/STD control: is integration the answer? *Afr J Reprod Health* 2001;**5**:29–46.
27. **deBruyn M**. *HIV/AIDS and Reproductive Health: Sensitive and Neglected Issues. A Review of The Literature. Recommendations For Action*. Chapel Hill: IPAS, 2005.
28. **Delvaux T**, Nostlinger C. Reproductive choice for women and men living with HIV: contraception, abortion and fertility. *Reprod Health Matters* 2007;**15** (29 Suppl):46–66.
29. **Myer L**, Rebe K, Morroni C. Missed opportunities to address reproductive health care needs among HIV-infected women in antiretroviral therapy programmes. *Trop Med Int Health* 2007;**12**:1484–9.
30. **Gruskin S**, Firestone R, Maccarthy S, *et al*. HIV and pregnancy intentions: do services adequately respond to women's needs? *Am J Public Health* 2008;**98**:1746–50.

FIGURE W1: STUDY SELECTION PROCESS

**Box W1: Database Search Strategy****PubMed Search #1:**

((((AIDS[sb])) OR ("Acquired Immunodeficiency Syndrome"[Mesh] OR "HIV"[Mesh])) AND ("Costs and Cost Analysis"[Mesh])) AND (integration OR integrated OR integrate OR converge OR convergence OR linkage OR linkages OR coordinated OR coordination OR coordinate OR vertical OR scope OR synergies[Title/Abstract]))"

**PubMed Search #2:**

"((((("Acquired Immunodeficiency Syndrome"[Majr] OR "HIV"[Majr])) OR (AIDS[sb]))) AND (((("Reproductive Health Services"[Majr]) OR "Family Planning Services"[Majr]) OR "Maternal Health Services"[Majr]) OR "Tuberculosis"[Majr])) AND ("Costs and Cost Analysis"[Mesh])"

**Eldis / Global Health / Econlit Search:**

(integrat\* or converg\* or linkage\$ or linked or coordinat\* or vertical or scope [Title]) AND (efficien\* or cost-effective\* or cost-benefit or economic\*) AND (HIV or AIDS) AND (program or programme or care or campaign or intervention or service).

**TABLE W1 STUDY  
QUALITY**

	Peer Reviewed vs. Grey Literature	Types of Studies	Clearly Described Alternatives?	Source of Effectiveness Estimates	Costing Scale	Costs Empirical or Modeled?	All Relevant Costs Included?	Sensitivity Analysis Conducted?
<b>VCT Studies</b>	10 peer reviewed 7 grey literature	4 CEA 13 cost analyses	5 stand-alone alternatives 4 'do nothing' alternatives 8 studies with no comparator	12 studies with no outcomes considered 2 outcomes modelled from study outputs 3 outcomes modelled	2 national models 14 small scale / pilot studies 1 small sample of an at-scale programme costed	13 empirical 1 modelled from study data 3 modelled	3 no 14 yes	11 studies with no sensitivity analysis 3 univariate sensitivity analysis 1 multivariate sensitivity analysis 1 univariate and multivariate sensitivity analysis 1 sensitivity analysis not shown
<b>TB Studies</b>	9 peer reviewed	5 CEA 3 cost analyses 1 least-cost analysis	5 'do nothing' alternatives 2 programmatic variations 2 studies with no comparator	2 studies with no outcomes considered 1 intermediate outputs measured empirically 3 outcomes modelled from study outputs 3 outcomes modelled	3 hypothetical patient cohorts 6 small scale / pilot studies	3 empirical 3 modelled from study data 3 modelled	2 not clear 7 yes	1 studies with no sensitivity analysis 4 univariate sensitivity analysis 1 multivariate sensitivity analysis 2 univariate and multivariate sensitivity analysis 1 sensitivity analysis not shown
<b>HIV Care and Treatment studies</b>	16 peer reviewed 2 grey literature	9 CEA 9 cost analyses	1 stand-alone alternative 9 'do nothing' alternatives 3 programmatic variations 5 studies with no comparator	8 studies with no outcomes considered 4 outcomes modelled 5 outcomes modelled from study outputs 1 intermediate outputs measured empirically	3 national models 2 hypothetical patient cohorts 7 small scale / pilot studies 6 small samples of at-scale programmes costed	7 empirical 4 modelled from study data 7 modelled	3 not clear 15 yes	7 studies with no sensitivity analysis 2 sensitivity analysis unclear 2 univariate sensitivity analyses 2 multivariate sensitivity analyses 5 univariate and multivariate sensitivity analyses
<b>FP Studies</b>	2 peer reviewed 2 grey literature	1 CEA 3 cost analyses	4 'do nothing' alternatives	1 studies with no outcomes considered 3 outcomes modelled	4 national models	4 modelled	4 not clear	3 studies with no sensitivity analysis 1 sensitivity analysis not shown
<b>High-Risk Group Studies</b>	3 peer reviewed	1 CEA 2 cost analyses	3 stand-alone alternatives	2 studies with no outcomes considered 1 outcomes empirically measured	3 small scale / pilot studies	3 empirical	1 no 2 yes	2 studies with no sensitivity analysis 1 sensitivity analysis not shown

- W1. UNAIDS. UNAIDS Terminology Guidelines, 2011.
- W2. Mays N, Pope C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. *J Health Serv Res Policy* 2005;**10** Suppl 1:6-20 doi: 10.1258/1355819054308576[published Online First: Epub Date]].
- W3. World Bank. Country and Lending Groups. Secondary Country and Lending Groups. <http://data.worldbank.org/about/country-classifications/country-and-lending-groups>.
- W4. Drummond MF. Guidelines for authors and peer reviewers of economic submissions to the BMJ. *BMJ* 1996(313):275-83
- W5. Shepperd S, Lewin S, Straus S, et al. Can We Systematically Review Studies That Evaluate Complex Interventions? *PLoS Med* 2009;**6**(8):e1000086
- W6. Twarir A, Maggwa BN, Askew I. Integration of STI and HIV/AIDS Services with MCH-FP Services: Case Study of the Mkomani Clinic Society in Mombasa, Kenya. In: Council TP, ed.: The Population Council, 1996.
- W7. Forsythe S, Arthur G, Ngatia G, et al. Assessing the cost and willingness to pay for voluntary HIV counselling and testing in Kenya. *Health Policy and Planning* 2002;**17**(2):187-95
- W8. Das R, Biswas K, Panda P, et al. Strengthening Financial Sustainability through Integration of Voluntary Counseling and Testing Services with Other Reproductive Health Services, 2007.
- W9. Liambila W, Warren C, Mullick S, et al. Feasibility, Acceptability, Effect and Cost of Integrating Counseling and Testing for HIV within Family Planning Services in Kenya. FRONTIERS final report. 2008
- W10. Menzies N, Abang B, Wanyenze R, et al. The costs and effectiveness of four HIV counseling and testing strategies in Uganda. *AIDS* 2009;**23**(3):395-401 doi: 10.1097/QAD.0b013e328321e40b[published Online First: Epub Date]].
- W11. Thielman NM, Chu HY, Ostermann J, et al. Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. *Am J Public Health* 2006;**96**(1):114-9 doi: AJPH.2004.056796 [pii]
- W12. Chee G, Smith K. Cost and Effectiveness Analysis of the Ndola Demonstration Project in Zambia, 2006.
- W13. Homan R, Mullick S, Maluka T. Cost of Introducing Two Different Models of Integrating VCT for HIV within Family Planning Clinics in South Africa. Conference on Linking Reproductive Health, Family Planning and HIV/AIDS in Africa, Addis Ababa, Ethiopia 2006
- W14. Reynolds HW, Beaton-Blaakman A, Burke H, et al. Integrating Family Planning Services into Voluntary Counseling and Testing Centers in Kenya, 2006:1-42.
- W15. Mullick S, Menziwa M, Mosery N. Feasibility, acceptability, effectiveness and cost of models of integrating HIV prevention and counseling and testing for HIV within family planning services in North West Province, South. FRONTIERS Final Report, 2008.

- W16. Bratt J, Torpey K, Kabaso M, et al. Costs of HIV/AIDS outpatient services delivered through Zambian public health facilities. *Tropical Medicine and International Health* 2011
- W17. Hausler HP, Sinanovic E, Kumaranayake L, et al. Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. *Bull World Health Organ* 2006;**84**(7):528-36 doi: S0042-96862006000700014 [pii][published Online First: Epub Date]].
- W18. Uhler LM, Kumarasamy N, Mayer KH, et al. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. *PLoS One* 2010;**5**(9) doi: 10.1371/journal.pone.0012747[published Online First: Epub Date]].
- W19. Vassall A, Seme A, Compernelle P, et al. Patient costs of accessing collaborative tuberculosis and human immunodeficiency virus interventions in Ethiopia. *Int J Tuberc Lung Dis* 2010;**14**(5):604-10
- W20. Kumar M, Birch S, Maturana A, et al. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India. *Health Policy* 2006;**77**(2):233-43 doi: S0168-8510(05)00181-8 [pii]
- W21. Sweat MD, O'Reilly KR, Schmid GP, et al. Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. *AIDS* 2004;**18**(12):1661-71 doi: 00002030-200408200-00007 [pii][published Online First: Epub Date]].
- W22. Perchal P, Assefa B, Collins L. Cost-effectiveness of Integrating HIV / STI Prevention in Maternal Health Programmes. Conference on Linking Reproductive Health, Family Planning and HIV/AIDS in Africa, Addis Ababa, Ethiopia 2006
- W23. Masobe P, Lee T, Price M. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients--a least-cost analysis. *S Afr Med J* 1995;**85**(2):75-81
- W24. Bell JC, Rose DN, Sacks HS. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. *AIDS* 1999;**13**(12):1549-56 doi: 00002030-199908200-00016 [pii][published Online First: Epub Date]].
- W25. Foster S, Godfrey-Faussett P, Porter J. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. *AIDS* 1997;**11**(7):919-25
- W26. Shrestha RK, Mugisha B, Bunnell R, et al. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda. *Int J Tuberc Lung Dis* 2006;**10**(6):656-62
- W27. Shrestha RK, Mugisha B, Bunnell R, et al. Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. *Int J Tuberc Lung Dis* 2007;**11**(7):747-54
- W28. Terris-Prestholt F, Kumaranayake L, Ginwalla R, et al. Integrating tuberculosis and HIV services for people living with HIV: costs of the Zambian ProTEST Initiative. *Cost effectiveness and resource allocation* : C/E 2008;**6**:2-2
- W29. Sutton BS, Arias MS, Chheng P, et al. The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia. *Int J Tuberc Lung Dis* 2009;**13**(6):713-8

- W30. WHO Three I's Meeting; 2008; Geneva, Switzerland.
- W31. Hansen K, Woelk G, Jackson H, et al. The cost of home-based care for HIV/AIDS patients in Zimbabwe. *AIDS Care* 1998;**10**(6):751-9
- W32. Chandler R, Decker C, Nziyige B. Estimating the Cost of Providing Home-based Care for HIV/AIDS in Rwanda. In: PHRPlus, ed. Bethesda, MD: Abt Associates, Inc., 2004.
- W33. Bikilla AD, Jerene D, Robberstad B, et al. Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia. *Cost Effectiveness and Resource Allocation* 2009;**7**(6)
- W34. Uys L, Hensher M. The cost of home-based terminal care for people with AIDS in South Africa. *S Afr Med J* 2002;**92**(8):624-8
- W35. Pitter C, Kahn JG, Marseille E, et al. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda. *J Acquir Immune Defic Syndr* 2007;**44**(3):336-43 doi: 10.1097/QAI.0b013e31802f12b5
- W36. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. *AIDS* 2005;**19**(12):1299-308 doi: 00002030-200508120-00008 [pii][published Online First: Epub Date]].
- W37. Stringer JS, Rouse DJ, Vermund SH, et al. Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. *J Acquir Immune Defic Syndr* 2000;**24**(4):369-77
- W38. Kitajima T, Kobayashi Y, Chaipah W, et al. Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand. *AIDS* 2003;**17**(16):2375-81 doi: 10.1097/01.aids.0000096859.36052.8e[published Online First: Epub Date]].
- W39. Rosen S, Long L, Sanne I. The Outcomes and Outpatient Costs of Different Models of Antiretroviral Treatment Delivery in South Africa. *Tropical medicine & international health : TM & IH* 2008;**13**:1005-15
- W40. Marseille E, Kahn JG, Pitter C, et al. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. *Appl Health Econ Health Policy* 2009;**7**(4):229-43 doi: 4 [pii]
- W41. Renaud A, Basenya O, de Borman N, et al. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. *AIDS care* 2009;**21**(11):1388-94
- W42. Bautista SA, Dmytraczenko T, Kombe G, et al. Costing of HIV/AIDS Treatment in Mexico. USAID: The Partners for Health Reformplus Project, Abt Associates Inc., 2003.
- W43. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis. *Cost effectiveness and resource allocation : C/E* 2006;**4**:20
- W44. Quentin W, Konig HH, Schmidt JO, et al. Recurrent Costs of HIV/AIDS-related Health Services in Rwanda: Implications for Financing. *Trop Med Int Health*. 2008;**13**(10):1245-56

- W45. Babigumira JB, Sethi AK, Smyth Ka, et al. Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. *PharmacoEconomics* 2009;**27**:963-73
- W46. Halperin DT, Stover J, Reynolds HW. Benefits and costs of expanding access to family planning programs to women living with HIV. *Aids* 2009;**23**:S123-S30
- W47. Reynolds HW, Janowitz B, Wilcher R, et al. Contraception to prevent HIV-positive births: current contribution and potential cost savings in PEPFAR countries. *Sexually transmitted infections* 2008;**84 Suppl 2**(Suppl II):ii49-53
- W48. Stover J, Group F, Fuchs N, et al. Costs and Benefits of Adding Family Planning to Services to Prevent Mother-to-Child Transmission of HIV. *Health Policy and Planning* 2003:1-16
- W49. Stover J, Dougherty L, Hamilton M. Are Cost Savings Incurred by Offering Family Planning Services at Emergency Plan HIV/AIDS Care and Treatment Facilities?: USAID, 2006.
- W50. Schackman BR, Leff JA, Botsko M, et al. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. *J Acquir Immune Defic Syndr* 2011;**56 Suppl 1**:S76-82 doi: 10.1097/QAI.0b013e31820a9a66
- W51. Weaver MR, Conover CJ, Proescholdbell RJ, et al. Cost-effectiveness Analysis of Integrated Care for People with HIV , Chronic Mental Illness and Substance Abuse Disorders. *Journal Of Mental Health Policy And Economics* 2009;**46**:33-46
- W52. Nyamuryekung'e K, Laukamm-Josten U. STD services for women at truck stop in Tanzania: evaluation of acceptable approaches. *East African Medical Journal* 1997;**74**(6):343-7
- W53. World Health Organization. Guidance on Provider-Initiated HIV Testing and Counseling in Health Facilities. Geneva, Switzerland: World Health Organization, 2007.